Privia Health Group and Azenta Compared in Head-to-Head Analysis

Analysts examine the strengths of these two medical companies to determine the superior business.

Published on Feb. 7, 2026

Got story updates? Submit your updates here. ›

Azenta (NASDAQ:AZTA) and Privia Health Group (NASDAQ:PRVA) are both medical companies, but a new analysis compares the two to determine which is the stronger business. The analysis looks at factors like net margins, return on equity, revenue, earnings per share, valuation, institutional ownership, and volatility to contrast the companies.

Why it matters

This head-to-head comparison provides valuable insights for investors looking to make informed decisions about which medical company stock to potentially add to their portfolio. Understanding the relative strengths and weaknesses of Azenta and Privia Health Group can help guide investment strategies in the healthcare sector.

The details

The analysis found that Privia Health Group has higher revenue and earnings per share than Azenta, though Azenta is trading at a lower price-to-earnings ratio, making it the more affordable of the two stocks currently. Privia Health Group also has a lower beta, indicating its share price is less volatile than the overall market compared to Azenta. Additionally, Privia Health Group scores better on 9 out of the 14 factors compared between the two companies.

  • The analysis was published on February 7, 2026.

The players

Azenta, Inc.

A provider of biological and chemical compound sample exploration and management solutions for the life sciences market.

Privia Health Group, Inc.

A national physician-enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care.

Got photos? Submit your photos here. ›

The takeaway

This comparative analysis of Azenta and Privia Health Group provides a useful framework for investors to evaluate the relative strengths of these two medical companies and make more informed decisions about where to allocate their capital in the healthcare sector.